குழு நிறுவனம் தி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from குழு நிறுவனம் தி நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In குழு நிறுவனம் தி நிறுவனம் Today - Breaking & Trending Today

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Raman Kant , Sosei Heptares , Anita Ganjoo , Hironoshin Nomura , Genentech Roche , Citigate Dewe Rogerson , Sosei Heptare , Shinichiro Nishishita , Sosei Group Corporation , Group Corporation The Company , Sosei Group , Corporate Communications , Tokyo Stock Exchange , Medistrava Consulting For International Media , Group Corporation , Miles Congreve , Chief Scientific Officer , Business Officer , Big Pharma , Specialty Pharma , Consumer Healthcare , Corporate Strategy , Regulatory Disclosures , Dewe Rogerson ,

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Prnewswire Sosei , Sosei Heptares , Hironoshin Nomura , Genentech Roche , Tim Tasker , Citigate Dewe Rogerson , Shinichiro Nishishita , Sosei Heptare , Sosei Group Corporation , Group Corporation The Company , Biohaven Pharmaceutical Holding Company Ltd , Sosei Group , Tokyo Stock Exchange , Medistrava Consulting For International Media , Group Corporation , Biohaven Pharmaceutical Holding Company , Executive Vice President , Chief Medical Officer , Biohaven Pharmaceutical Ireland , Corporate Strategy , Dewe Rogerson , Japanese Media , International Media , ஒன்றுபட்டது கிஂக்டம் , ஜெநிஂடெக் ரோச் ,

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Share this article
Share this article
TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ( Formosa ) has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.
APP13007 was originally designed and developed at Activus Pharma Inc. ( Activus ), formerly a wholly owned subsidiary of the Company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a leading manufacturer of Active Pharmaceutical Ingredients ( APIs ) listed on the Taiwan Stock Exchange. The divestment was part of Sosei Heptares redirected ....

United Kingdom , United States , Prnewswire Sosei , Sosei Heptares , Hironoshin Nomura , Shinichi Tamura , States Clinicaltrials , Genentech Roche , Shinichiro Nishishita , Citigate Dewe Rogerson , Sosei Heptare , Sosei Group Corporation , International Media , Group Corporation The Company , Sosei Group , Tokyo Stock Exchange , Taiwan Stock Exchange , Activus Pharma Inc , Activus Pure Nanoparticle Technology , Formosa Laboratories Inc , Formosa Pharmaceuticals Inc , Group Corporation , Formosa Pharmaceuticals , Activus Pharma , Formosa Laboratories , Active Pharmaceutical Ingredients ,

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

Share this article
Share this article
TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ( Metrion ), the specialist ion channel CRO and drug discovery company.
Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches. ....

United Kingdom , Prnewswire Sosei , Metrion Biosciences , Sosei Heptares , Rob Cooke , Andrew Southan , Genentech Roche , Metrion Bioscience , Sosei Heptare , Sosei Group Corporation , Metrion Biosciences Limited , Group Corporation The Company , Sosei Group , Tokyo Stock Exchange , Group Corporation , Chief Technology Officer , Structure Based Drug Discovery , Captor Therapeutics , Chief Executive Officer , Sosei Heptare Structure Based Drug Discovery , ஒன்றுபட்டது கிஂக்டம் , கொள்ளை சமைக்க , ஆண்ட்ரூ தென்கிழக்கு , ஜெநிஂடெக் ரோச் , குழு நிறுவனம் தி நிறுவனம் , டோக்கியோ ஸ்டாக் பரிமாற்றம் ,

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target

Share this article
Share this article
TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability, with PharmEnable s proprietary advanced artificial intelligence (AI)-enabled and medicinal chemistry technologies (ChemUniverse and ChemSeek) to identify novel, highly specific drug leads for further development. ....

United Kingdom , Sosei Heptares , Hironoshin Nomura , Sue Charles , Genentech Roche , Citigate Dewe Rogerson , Sosei Heptare , Jelena Aleksic , Shinichiro Nishishita , Sosei Group Corporation , International Media , Group Corporation The Company , University Of Cambridge , Sosei Group , Tokyo Stock Exchange , Group Corporation , Chief Scientific Officer , Chief Executive Officer , Investor Relations , Corporate Strategy , Regulatory Disclosures , Dewe Rogerson , Japanese Media , David Dible , Medical Pharmaceuticals , Health Care Amp Hospitals ,